Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 479

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 479
---
 or other intangible assets are recorded. Bitcoin Securities Purchase Agreement On September 23, 2025, the Company entered into a Securities Purchase Agreement (the “Semnur/Biconomy SPA”) with an Biconomy PTD.LTD (“Biconomy”). Pursuant to the Semnur/Biconomy SPA, the Company agreed to issue and sell, and Biconomy agreed to purchase, an aggregate of 6,250,000shares (the “Biconomy Shares”) of New Semnur Common Stock, for a purchase price of $ 16.00per share, payable in Bitcoin blockchain (“Bitcoin”), with such amount of Bitcoin equal to the quotient of (A) the buyer’s respective aggregate purchase price divided by (B) the spot exchange rate for Bitcoin as published by Coinbase.com at 8:00 p.m. (New York City time) on the trading day immediately prior to the closing date of the purchase.

<div align='center'>F-102</div>

PART II INFORMATION NOT REQUIRED IN THE PROSPECTUS Item 13. Other Expenses of Issuance and Distribution. The following table sets forth all expenses to be paid by Semnur Pharmaceuticals, Inc. (the “Registrant”) in connection with the sale of the Common Stock being registered. The security holders will not bear any portion of such expenses. All amounts shown are estimates except for the registration fee.

| SEC registration fee                                     |     | $ | 267,137.35 |
| Legal fees and expenses                                  |     |   |    150,000 |
| Accounting fees and expenses                             |     |   |     50,000 |
| Printing, transfer agent fees and miscellaneous expenses |     |   |     25,000 |
| Total                                                    |     | $ | 492,137.35 |

Item 14. Indemnification of Directors and Officers. Section 102 of the General Corporation Law of the State of Delaware (“DGCL”) permits a corporation to eliminate or limit the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty to the corporation or its stockholders, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase or redemption in violation of the DGCL or derived an improper personal benefit, or, with respect